| No. of Observations | No. of Cases | Person years of follow-up | Incidence density (1/1000 person-years) | Model 1 Hazard ratio (95%CI) | P value | Model 2 Hazard ratio (95%CI) | P value |
---|---|---|---|---|---|---|---|---|
BP under control | 3141 | 406 | 32,394 | 12.53 | Â | Â | Â | Â |
 Q1 | 912 | 167 | 9235 | 18.08 | 1.00 |  | 1.00 |  |
 Q2 | 853 | 116 | 8873 | 13.07 | 1.01 (0.79–1.29) | 0.927 | 1.04 (0.81–1.33) | 0.759 |
 Q3 | 690 | 66 | 7217 | 9.15 | 0.86 (0.64–1.16) | 0.321 | 0.88 (0.65–1.19) | 0.410 |
 Q4 | 686 | 57 | 7069 | 8.06 | 0.80 (0.58–1.10) | 0.170 | 0.82 (0.59–1.15) | 0.253 |
Stage 1 hypertension | 11,508 | 1106 | 121,101 | 9.13 | Â | Â | Â | Â |
 Q1 | 2536 | 437 | 26,195 | 16.68 | 1.00 |  | 1.00 |  |
 Q2 | 2857 | 290 | 30,126 | 9.63 | 0.77 (0.67–0.90) | < 0.001* | 0.78 (0.67–0.91) | 0.001* |
 Q3 | 2969 | 185 | 31,634 | 5.85 | 0.58 (0.48–0.69) | < 0.001* | 0.59 (0.49–0.71) | < 0.001* |
 Q4 | 3146 | 194 | 33,146 | 5.85 | 0.64 (0.53–0.77) | < 0.001* | 0.66 (0.55–0.80) | < 0.001* |
Stage 2 hypertension | 4048 | 594 | 42,272 | 14.05 | Â | Â | Â | Â |
 Q1 | 1057 | 214 | 10,833 | 19.75 | 1.00 |  | 1.00 |  |
 Q2 | 1051 | 164 | 11,009 | 14.90 | 0.99 (0.81–1.22) | 0.938 | 1.00 (0.81–1.23) | 0.974 |
 Q3 | 1015 | 131 | 10,777 | 12.16 | 0.98 (0.78–1.23) | 0.864 | 1.01 (0.80–1.27) | 0.957 |
 Q4 | 925 | 85 | 9653 | 8.81 | 0.79 (0.60–1.04) | 0.095 | 0.83 (0.62–1.10) | 0.192 |
Stage 3 hypertension | 1482 | 313 | 15,299 | 20.46 | Â | Â | Â | Â |
 Q1 | 414 | 125 | 4129 | 30.27 | 1.00 |  | 1.00 |  |
 Q2 | 405 | 81 | 4247 | 19.07 | 0.79 (0.59–1.05) | 0.106 | 0.80 (0.60–1.07) | 0.129 |
 Q3 | 372 | 57 | 3907 | 14.59 | 0.65 (0.47–0.91) | 0.011* | 0.67 (0.49–0.96) | 0.027* |
 Q4 | 291 | 50 | 3016 | 16.58 | 0.87 (0.60–1.25) | 0.442 | 0.89 (0.61–1.30) | 0.552 |